A Phase 2 interventional study of Synera (lidocaine 70mg/tetracaine 70mg) in Pain, Phlebotomy and Palliative Care, sponsored by US Oncology Research. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-25.
Sponsored by US Oncology Research (part of Sarah Cannon Research Institute) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 204 studies testing lidocaine in Pain — 19 open to participants now, 19 under way, 1 of them phase 3. Lidocaine · Pain.
Among the 204 studies testing lidocaine in Pain, this one is the 110th largest by enrollment of the 203 interventional ones that give a count, is one of 17 that started in 2013, is one of 17 in phase 2, and was the 75th registered.
10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.
Browse Pain studies →19 of the 204 studies testing lidocaine in Pain are open now, in 9 countries. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Northwell Health · Sites in United States
Ages 18+ · Women only
Montefiore Medical Center · Sites in United States
Ages 18–50 · Women only
Cairo University · Sites in Egypt
Ages 18–65 · Healthy volunteers
Ain Shams University · Sites in Egypt
Ages 18–40 · Women only
By country, each count listing its studies:
Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
204 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 32 · Phase 3 34 · Phase 4 63
First in 2002; this study’s year is marked. 17 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is close to the median of 66 across 8,502 interventional studies indexed under Pain.
Median enrollment 66 across the 203 interventional studies. Of the 157 that completed or were terminated, 66 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 204 have an industry lead sponsor. The 10 most frequent:
This study is registered under US Oncology Research, one of the names counted as Sarah Cannon Research Institute. Under that name alone:
US Oncology Research is the lead sponsor of 29 studies on the registry; 1 is open to participants now.
Sarah Cannon Research Institute has 1 study filed under Pain — fewer than ten, so there is no comparison to draw.
5 of the studies testing lidocaine in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07785674Mayo ClinicArm Elevation for Prevention of Propofol Injection Pain | 2027-01 |
| NCT07883473Shaheed Zulfiqar Ali Bhutto Medical UniversityPudendal Nerve Block for Pain Relief During Episiotomy Repair | 2027-01-31 |
| NCT07889687Northwell HealthThis Study is Comparing Pain Outcomes After Urethral Bulking When Participants Are Randomized to Two Different Pain Medication Regimens. | 2027-04 |
| NCT07546370Monakshi SawhneyThe Effectiveness of Topical Prilocaine-Lidocaine Cream Plus Acetaminophen and Naproxen Compared to Lidocaine Injection Plus Acetaminophen and Naproxen to Manage Pain During IntraUterine Device Insertion | 2027-04-14 |
| NCT07048769Montefiore Medical CenterParacervical Block for Pain Reduction in Saline Infusion Sonograms | 2027-07 |
Add all 5 to your calendar (.ics) → With an account.
Among the 204 studies testing lidocaine in Pain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Synera, which is a heated topical patch containing both lidocaine and tetracaine, is intended to reduce the pain associated with venipuncture and superficial dermatologic procedures by numbing the skin. This study will test the effectiveness of the Synera lidocaine/tetracaine patch when administered for 30 ± 5 minutes to provide dermal anesthesia in adult oncology patients undergoing venipuncture as part of their care, for treatment or diagnostics (laboratory or imaging). Compared to the use of the placebo patch, this study hypothesizes that the difference of 1 cm on the 0-10 visual analogue scale (VAS) will be observed 30 minutes after the use of the Synera patch. Pain intensity will be assessed by a 0-10 VAS
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
First application: Synera (lidocaine 70mg/tetracaine 70mg) patch; Second application: Placebo patch
Drug: Synera (lidocaine 70mg/tetracaine 70mg)
First application: Placebo patch; Second application: Synera (lidocaine 70mg/tetracaine 70mg) patch
Drug: Synera (lidocaine 70mg/tetracaine 70mg)
Drug page: Lidocaine
All subjects will receive 2 patch applications during this study: one Synera, one placebo. The 2 patch applications must be done on separate days. Only 1 patch will be used per application. Arm 1 subjects will receive Synera patch for the 1st application, and placebo for the second. Arm 2 patients will receive placebo patch for the 1st application, and Synera patch for the second.
Also known as: Synera
Percentage of Patients With No or Minor Pain (VAS<3)
The primary efficacy endpoint is the subject's report of pain intensity regarding the venipuncture using a 0-10 VAS. The VAS \<3 is considered as patients with no or minor pain and would be compared between 2 groups.
Time frame: 30 minutes after the venipuncture.
Percentage of Patients With No Pain (VAS=0)
The primary efficacy endpoint is the subject's report of pain intensity regarding the venipuncture using a 0-10 VAS. The VAS =0 is considered as patients with no pain and would also be compared between 2 groups.
Time frame: 30 minutes after the venipuncture.
Global Assessment of Satisfaction With Venipuncture
Rates of Satisfied and very satisfied are used to be compared between two groups.
Time frame: 30 minutes after the venipuncture.
| Milestone | Synera First, Then Placebo | Placebo First, Then Synera |
|---|---|---|
| Started | 32 | 29 |
| Completed | 28 | 26 |
| Not completed | 4 | 3 |
| Withdrew: Received 1 patch | 2 | 1 |
| Withdrew: No patch received | 2 | 2 |
The primary efficacy endpoint is the subject's report of pain intensity regarding the venipuncture using a 0-10 VAS. The VAS \<3 is considered as patients with no or minor pain and would be compared between 2 groups.
| percentage of participants | Synera | Placebo |
|---|---|---|
| Percentage of Patients With No or Minor Pain (VAS<3) | 38.0 | 21.3 |
The primary efficacy endpoint is the subject's report of pain intensity regarding the venipuncture using a 0-10 VAS. The VAS =0 is considered as patients with no pain and would also be compared between 2 groups.
| percentage of participants | Synera | Placebo |
|---|---|---|
| Percentage of Patients With No Pain (VAS=0) | 19.4 | 8.3 |
Rates of Satisfied and very satisfied are used to be compared between two groups.
| percentage of participants | Synera | Placebo |
|---|---|---|
| Global Assessment of Satisfaction With Venipuncture | 74.0 | 53.7 |
Collected over During the whole treatment period, up to 30 days following last dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Synera | — | 0/54 (0%) | 25/54 (46.3%) |
| Placebo | — | 0/54 (0%) | 18/54 (33.3%) |
| Event | Synera | Placebo |
|---|---|---|
| WELL-DEFINED ERYTHEMASkin and subcutaneous tissue disorders | 14/54 | 7/54 |
| VERY SLIGHT ERYTHEMASkin and subcutaneous tissue disorders | 11/54 | 11/54 |
ITT population
| Age, Continuous(years) | Synera First, Then Placebo | Placebo First, Then Synera | Total |
|---|---|---|---|
| Mean | 60.8 ± 11.2 | 60.3 ± 13.0 | 60.5 ± 12.0 |
| Sex: Female, Male(Participants) | Synera First, Then Placebo | Placebo First, Then Synera | Total |
|---|---|---|---|
| Female | 20 | 14 | 34 |
| Male | 12 | 15 | 27 |
| Race/Ethnicity, Customized(participants) | Synera First, Then Placebo | Placebo First, Then Synera | Total |
|---|---|---|---|
| Caucasian | 31 | 24 | 55 |
| African American | 1 | 4 | 5 |
| Indian | 0 | 1 | 1 |
| Region of Enrollment(participants) | Synera First, Then Placebo | Placebo First, Then Synera | Total |
|---|---|---|---|
| United States | 32 | 29 | 61 |
The record gives a start of Jan 2013, a primary completion of Feb 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lidocaine